Cargando…

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gujar, Shashi A, Clements, Derek, Lee, Patrick WK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010537/ https://www.ncbi.nlm.nih.gov/pubmed/24804161 http://dx.doi.org/10.4161/onci.27622

Ejemplares similares

Pre-surgical oncolytic virotherapy improves breast cancer outcomes
por: Mullins-Dansereau, Victor, et al.
Publicado: (2019)

Role of the complement system in NK cell-mediated antitumor T-cell responses
por: Janelle, Valérie, et al.
Publicado: (2014)

Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy
por: Alvarez-Breckenridge, Christopher A., et al.
Publicado: (2013)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

Retinoic acid on stage in antitumor immunity
por: Guo, Yanxia, et al.
Publicado: (2013)

Targeting coagulation to unlock antitumor immunity?
por: Galmiche, Antoine, et al.
Publicado: (2022)

Restoration of defective cross-presentation in tumors by gemcitabine
por: McDonnell, Alison M, et al.
Publicado: (2015)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

Crucial role of inflammatory monocytes in antitumor immunity
por: Pommier, Arnaud, et al.
Publicado: (2013)

Engineering effective T-cell based antitumor immunity
por: Gruber, Thomas, et al.
Publicado: (2013)

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
por: Zhang, Bin, et al.
Publicado: (2020)

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)

Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy
por: Konda, Prathyusha, et al.
Publicado: (2020)

Potentiating antitumor immunity with αGC-loaded exosomes
por: Gehrmann, Ulf, et al.
Publicado: (2013)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

High endothelial venules: Help or hindrance in the quest for antitumor immunity?
por: Gallimore, Awen, et al.
Publicado: (2013)

Activation of systemic antitumor immunity via TRAIL-induced apoptosis
por: James, Britnie R., et al.
Publicado: (2012)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells
por: Fonteneau, Jean-François, et al.
Publicado: (2013)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

A Janus-faced role of the unfolded protein response in antitumor immunity
por: Mahadevan, Navin R., et al.
Publicado: (2013)

Monocyte-derived dendritic cells: Emerging players in the antitumor immune response
por: Kuhn, Sabine, et al.
Publicado: (2013)

B7-H4 is a positive regulator of antitumor immunity
por: Rahbar, Ramtin, et al.
Publicado: (2015)

A clinically useful approach to enhance immunological memory and antitumor immunity
por: Berezhnoy, Alex, et al.
Publicado: (2014)

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
por: Eyob, Henok, et al.
Publicado: (2013)

Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses
por: Pan, Ping-Ying, et al.
Publicado: (2013)

Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses
por: Goc, Jérémy, et al.
Publicado: (2014)

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?
por: Godet, Yann, et al.
Publicado: (2012)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response
por: Sosnowska, Anna, et al.
Publicado: (2019)

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
por: Verbrugge, Inge, et al.
Publicado: (2012)

The short and sweet of T-cell therapy: Restraining glycolysis enhances the formation of immunological memory and antitumor immune responses
por: Sukumar, Madhusudhanan, et al.
Publicado: (2014)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3dthgtddm9ht9fhog3ctkcge1s